Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2015-10-13 Investor Presentation
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Investor Presentation Classification · 95% confidence The document is titled "Bone Therapeutics annonce sa participation aux principaux Forum Investisseurs du T4 2015" (Bone Therapeutics announces its participation in the main Investor Forums of Q4 2015). It lists several upcoming investor conferences and events (Portzamparc Biotech Seminar, Société Générale Healthcare Conference, KBC Benelux & Healthcare Event, etc.) where the company management will be present. This content is a schedule or announcement regarding investor outreach and participation in external events, not a formal financial report (like 10-K, IR, ER) or a presentation itself (IP). This type of announcement, detailing planned investor engagement, fits best under the general category of investor relations communication, which often falls under Regulatory Filings (RNS) if a more specific category like Investor Presentation (IP) or Earnings Release (ER) is not applicable. Since it is an announcement about future investor meetings rather than the presentation material itself, RNS is the most appropriate fallback, although it is closely related to investor relations activities.
2015-10-13 French
20150922_Bone Therapeutics_Interim Financial Report H1 2015.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Financial Report H1 2015' and contains comprehensive financial statements, including a balance sheet, income statement, and cash flow analysis for the six-month period ending June 30, 2015. It provides detailed management commentary on operational and financial performance, meeting the criteria for an Interim/Quarterly Report (IR). H1 2015
2015-09-22 English
20150922_Rapport H1 2015.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Rapport Financier Semestriel' (Semi-annual Financial Report) for the first half of 2015. It contains detailed financial statements, management discussion and analysis (MDA), operational highlights, and cash flow analysis. It is a comprehensive report covering a period shorter than a full fiscal year, which fits the definition of an Interim/Quarterly Report (IR). It is not an announcement of a report (RPA) as it contains the full content of the financial analysis. H1 2015
2015-09-22 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 98% confidence The document is a press release dated September 18, 2015, titled "Bone Therapeutics annonce la publication prochaine de ses résultats financiers du premier semestre 2015" (Bone Therapeutics announces the upcoming publication of its first-half 2015 financial results). The core content is an announcement that the financial results for the first half of 2015 will be published on September 22, 2015. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports, rather than the report itself (which would likely be an IR or ER, depending on the context, but here it is explicitly announcing the release date). The document length (5119 chars) is moderate, but the content is purely an announcement of a future event (the release of the H1 results).
2015-09-21 French
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 98% confidence The document is titled "Bone Therapeutics Notice of Half Year Results 2015" and explicitly states that the company "will announce its half year results for the six-month period ended 30 June 2015 on September 22". This text is a brief announcement *about* the upcoming release of financial results for an interim period (half year). It is not the comprehensive report itself (which would be classified as IR). Since it is an announcement regarding the publication of results, it fits the definition of a Report Publication Announcement (RPA). It is too specific to be a general Regulatory Filing (RNS).
2015-09-21 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Legal Proceedings Report Classification · 99% confidence The document is a press release dated September 7, 2015, from Bone Therapeutics announcing that they have successfully treated the second cohort of patients in their Phase I/IIA clinical study for ALLOB® for delayed union fractures. It details the safety review by the Data Safety Monitoring Board (DSMB) and provides updates on the study protocol, patient recruitment, and a sub-study on biodistribution. This type of announcement, focusing on clinical trial progress, safety updates, and operational milestones, is characteristic of an Earnings Release (ER) if it were tied to a quarterly report, or more generally, a Regulatory Filing (RNS) if it's a standalone operational update not fitting other specific categories. Since it is a specific operational update about a clinical trial milestone, and not a comprehensive financial report (10-K, IR), a management discussion (MDA), or a formal regulatory filing like a DIRS or DIV, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if such updates are bundled there. Given the content is a specific, time-sensitive operational update rather than a summary of financial results, RNS is the most appropriate general category for non-standard, material operational news, although ER often includes such operational highlights. However, since it is a press release detailing clinical progress, it is a material event announcement. In the absence of explicit quarterly financial figures or a clear reference to an earnings report, RNS (Regulatory Filings/General Announcement) is the safest classification for a material operational update press release.
2015-09-07 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.